ArticleVeterinary research communications2025
Combining network pharmacology and metabonomics to explore the mechanism of baicalin inhibiting PRRSV replication.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antiviral Activity of Baicalin Against PRRSV In Vitro and in Infected Piglets.Veterinary sciences · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is widely prevalent and causes significant economic losses to the global swine industry. Currently available vaccines provide insufficient protection, and there are no clinically approved antiviral treatments specifically targeting PRRSV. Accordingly, developing safe and potent measures for PRRS prevention and control remains an urgent priority. Yinhuang soluble powder is a traditional Chinese medicinal preparation mainly composed of baicalin and chlorogenic acid, with baicalin serving as its principal active ingredient, which demonstrates significant potential in antiviral research. However, current research on baicalin's anti-PRRSV activity is notably lacking, with its molecular mechanisms still not fully elucidated. In this study, in vitro experiments demonstrated that both Yinhuang soluble powder and baicalin not only effectively inhibited PRRSV replication but also interfered with the viral replication cycle, concurrently demonstrating significant downregulation of pro-inflammatory cytokines. Network pharmacological screening identified eight core targets of baicalin against PRRSV, namely MAPK14, MAPK10, MAPK8, NF-κB1, MAPK1, SRC, IL-6, and TP53. Molecular docking revealed baicalin's strong binding affinity to the core targets, with free binding energies below - 7.0 kcal/mol. In addition, metabolomics identified 29 metabolites associated with the anti-PRRSV effects of baicalin, the main components of which were glycerophospholipids, glycerolipids, and fatty acyls, and the principal metabolic pathways through which baicalin exerts its anti-PRRSV effects are glycerophospholipid and glycerolipid metabolism. In conclusion, this study demonstrates that baicalin exhibits promising anti-PRRSV efficacy, proposing new insights for PRRS prevention and treatment.
Indexed as
Identifiers
40986108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.